Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.44 |
| ▸ | TACR3 | P29371 | 12/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ERG | P11308 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928617 | 0.91 | TACR3 (0.44) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL929653 | 0.90 | GRM5 (0.47) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL928665 | 0.90 | GRM5 (0.44) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL3815625 | 0.87 | TACR3 (0.44) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL931448 | 0.86 | TACR3 (0.51) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL930170 | 0.86 | P2RX7 (0.59) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL930520 | 0.86 | TACR3 (0.45) | P2RX7TACR3KCNH2TACR2TACR1 | |
| SCHEMBL928488 | 0.86 | P2RX7 (0.46) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL928660 | 0.85 | TACR3 (0.44) | P2RX7TACR3KCNH2CYP1A2CYP2C9 | |
| SCHEMBL929937 | 0.85 | TACR3 (0.51) | TACR3KCNH2CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | US | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | GRM5, GRIK5, GRK5 | P2RX7 71/4885TACR3 486/4885KCNH2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.